Scrip Asia 100: Sales blown off course by currency headwinds
This article was originally published in Scrip
Executive Summary
Fiscal 2013 was a difficult year for Asian drug producers. 2013 drug revenues were $128bn, 5.1% down on 2012 levels ($136bn) across the 85 publicly-traded pharmaceutical companies that constitute the Scrip Asia 100 (see Table 1 for detail).
You may also be interested in...
Gender Diversity In Pharma: Caught Between Desire And Reality
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
Women In High Places: Slow Progress In Pharma
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
Stock Scan April 2018: Pharma's Fizz Falls Flat
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.